Patsnap Life Science

By discovering the latest data on pharmaceutical #Clinical #Patent #News #indication #Pipeline to empower IP and R&D teams make more strategic decisions.

[Patsnap Life Science @PatSnapLS]

Freeline has reported encouraging initial clinical data from the first cohort of its Phase 1/2 GALILEO-1 Trial, evaluating FLT201, a novel gene therapy candidate for Gaucher Disease.

For more details, visit: https://t.co/j3o3S0V5mc.

[Patsnap Life Science @PatSnapLS]

Smart Immune begins administering its ProTcell Therapy SMART101 to leukemia patients in the ReSET-02 Phase I/II study https://t.co/Crd6ngaUNb

[Patsnap Life Science @PatSnapLS]

Longeveron has released positive top-line results from its CLEAR MIND Phase 2a Clinical Trial evaluating Lomecel-B for treating mild Alzheimer's Disease.

For more information, visit: https://t.co/j3o3S0VDbK.

[Patsnap Life Science @PatSnapLS]

Fenofibric acid Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs, Mechanisms of Action, and Drug Target https://t.co/K2mCDX2Td8

[Patsnap Life Science @PatSnapLS]

Kineta has reported encouraging safety and biomarker data from its Phase 1/2 VISTA-101 Clinical Trial, specifically from the KVA12123 monotherapy.

For more details, visit: https://t.co/j3o3S0VDbK.

[Patsnap Life Science @PatSnapLS]

Deoxycholic acid: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target https://t.co/W99csbJZqd

[Patsnap Life Science @PatSnapLS]

Eli Lilly is set to acquire POINT Biopharma as part of its expansion into next-generation radioligand therapies, bolstering its oncology capabilities.

For details, visit: https://t.co/j3o3S0VDbK.

[Patsnap Life Science @PatSnapLS]

Inozyme Pharma reports promising initial results from ongoing INZ-701 phase 1/2 studies in adults with ENPP1 and ABCC6 (PXE) deficiencies https://t.co/tQIyTEXZaU

[Patsnap Life Science @PatSnapLS]

Novartis' investigational drug, iptacopan, has shown promising results in a Phase III study for patients with IgA nephropathy.

For more information, visit: https://t.co/j3o3S0VDbK.

[Patsnap Life Science @PatSnapLS]

Potential Therapeutic Drug for Autoimmune and Neurodegenerative Diseases - RIPK1 Inhibitors https://t.co/RPpmv4bKJs

[Patsnap Life Science @PatSnapLS]

The FDA has granted approval for Biogen's TOFIDENCE, a biosimilar referencing ACTEMRA, providing an alternative treatment option. This development expands patient access and promotes competition in the biologics market.

For more details, visit: https://t.co/j3o3S0VDbK.

[Patsnap Life Science @PatSnapLS]

Decoding Hydrochlorothiazide/Lisinopril: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target https://t.co/FXVXyAPmvW

[Patsnap Life Science @PatSnapLS]

Novartis has achieved a significant milestone by completing the divestment of its front-of-eye ophthalmology assets.

For more detailed information, please visit: https://t.co/j3o3S0VDbK.

[Patsnap Life Science @PatSnapLS]

Decoding Tibolone: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target https://t.co/c5zmTzI5TN

[Patsnap Life Science @PatSnapLS]

The Biologics License Application (BLA) for Odronextamab, proposed for the treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL), has been accepted for FDA priority review.

For more details, please visit: https://t.co/j3o3S0VDbK.

[Patsnap Life Science @PatSnapLS]

Bristol Myers Squibb reports improved survival in operable non-small cell lung cancer patients with a regimen of Opdivo (nivolumab) and chemotherapy https://t.co/ddeP5aM3a0

[Patsnap Life Science @PatSnapLS]

Ginkgo Bioworks (NYSE: DNA) announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug candidates.

For more information, please visit: https://t.co/j3o3S0VDbK.

[Patsnap Life Science @PatSnapLS]

Sulfathiazole Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs, Mechanisms of Action, and Drug Target https://t.co/d5XjdAWs8M

[Patsnap Life Science @PatSnapLS]

Abeona Therapeutics has submitted a Biologics License Application (BLA) to the U.S. FDA, with a request for priority review and approval of EB-101.

For more information, please visit: https://t.co/j3o3S0V5mc.

[Patsnap Life Science @PatSnapLS]

Decoding Methoxsalen: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target https://t.co/lPqdHAdyLY